CD19 and B-cell chronic lymphocytic leukemia: Having confirmed inhibitor's on‐target activity, we next assessed the effect of SEL24‐B489 (1‐10 μmol/L, 48 hours) on viability of CD19+ CLL cells obtained from peripheral blood of 23 treatment‐naïve patients and 5 healthy individuals (Table S3).